Cargando…

Healthcare Costs of Clostridioides difficile Infection in Commercially Insured Younger Adults

In a US adult population aged <65 years, attributable costs due to Clostridioides difficile infection (CDI) were highest in persons with hospital onset and lowest in those with community-associated CDI treated outside a hospital. The economic burden of CDI in younger adults underscores the need f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahrmann, John M, Olsen, Margaret A, Keller, Matthew R, Yu, Holly, Dubberke, Erik R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368308/ https://www.ncbi.nlm.nih.gov/pubmed/37496610 http://dx.doi.org/10.1093/ofid/ofad343

Ejemplares similares

752. Costs Attributable to Clostridioides difficile Infection in the Presence of Differential Mortality
por: Sahrmann, John, et al.
Publicado: (2021)

Increased Incidence and Risk of Septicemia and Urinary Tract Infection After Clostridioides difficile Infection
por: Olsen, Margaret A, et al.
Publicado: (2023)

Risk factors for hospital-onset Clostridioides difficile infections before and during the severe acute respiratory syndrome coronavirus 2 pandemic
por: Kwon, Jennie H., et al.
Publicado: (2023)

Burden of Clostridium difficile on the Healthcare System
por: Dubberke, Erik R., et al.
Publicado: (2012)

16. Attributable Mortality, Healthcare Costs and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2021)

Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees
por: Yu, Holly, et al.
Publicado: (2022)

393. Healthcare and Out-of-Pocket Costs Associated With Clostridioides difficile Infection Among US Adults 18–64 Years of Age
por: Yu, Holly, et al.
Publicado: (2022)

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection
por: Dubberke, Erik R., et al.
Publicado: (2022)

Comparing intervention strategies for reducing Clostridioides difficile transmission in acute healthcare settings: an agent-based modeling study
por: Stephenson, Brittany, et al.
Publicado: (2020)

Economic Impact of Recurrent Clostridioides difficile Infection in the USA: A Systematic Literature Review and Cost Synthesis
por: Reveles, Kelly R., et al.
Publicado: (2023)

Quantifying Transmission of Clostridium difficile within and outside Healthcare Settings
por: Durham, David P., et al.
Publicado: (2016)

691. Association between Clostridioides difficile Colonization, Rectal Swab NAAT Positivity, and Environmental Contamination
por: Lee, Mary Morgan, et al.
Publicado: (2023)

Effect of fecal microbial transplantation on Clostridioides difficile infection: dysbiosis, metabolites and health related quality of life
por: Garey, Kevin W, et al.
Publicado: (2023)

Epidemiology of Primary and Recurrent Healthcare-Associated and Community-Associated Pediatric Clostridioides difficile Infection in Canada, 2015–2020
por: Silva, Anada, et al.
Publicado: (2023)

Multi-omics investigation of Clostridioides difficile-colonized patients reveals pathogen and commensal correlates of C. difficile pathogenesis
por: Fishbein, Skye RS, et al.
Publicado: (2022)

Propensity-Matched Cost of Clostridioides difficile Infection Overdiagnosis
por: Madden, Gregory R, et al.
Publicado: (2020)

Costs Associated with the Treatment of Clostridioides Difficile Infections
por: Sierocka, Aleksandra, et al.
Publicado: (2021)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

Clostridioides difficile Prevalence in the United States: National Inpatient Sample, 2016 to 2018
por: Petersen, Molly R, et al.
Publicado: (2021)

Impact of Updated Clinical Practice Guidelines on Outpatient Treatment for Clostridioides difficile Infection and Associated Clinical Outcomes
por: Dubberke, Erik R, et al.
Publicado: (2022)

Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection
por: Dubberke, Erik R, et al.
Publicado: (2020)

Increasing Age Has Limited Impact on Risk of Clostridium difficile Infection in an Elderly Population
por: Olsen, Margaret A, et al.
Publicado: (2018)

396. Incidence and Attributable Mortality of Clostridioides difficile Infection Among US Adults 18-64 Years of Age
por: Yu, Holly, et al.
Publicado: (2022)

Bezlotoxumab in the treatment of Clostridioides difficile infections: a real-life experience
por: Olmedo, María, et al.
Publicado: (2022)

Prevalence and impact of Clostridioides difficile infection among hospitalized patients with coranavirus disease 2019
por: Allegretti, Jessica R, et al.
Publicado: (2021)

Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection
por: Eriksen, Lotte Lindgreen, et al.
Publicado: (2021)

A systematic review of real-world healthcare resource use and costs of Clostridioides difficile infections
por: Malone, Daniel C., et al.
Publicado: (2023)

Association between Antibiotic Consumption and Incidence of Clostridioides difficile Infection in a Hospital
por: Kim, Bongyoung, et al.
Publicado: (2020)

Effect of Reduced Fluoroquinolone Use on Cephalosporin Use, Susceptibilities and Clostridioides difficile Infections
por: Wren, Callyn Mariah, et al.
Publicado: (2022)

678. Changes in the Clostridioides difficile Infection (CDI) Treatment Pattern Pre-Post Clinical Guideline Update in 2021 and Variations across Hospitals
por: Dubberke, Erik R, et al.
Publicado: (2023)

Human Colon Cancer–Derived Clostridioides difficile Strains Drive Colonic Tumorigenesis in Mice
por: Drewes, Julia L., et al.
Publicado: (2022)

Performance of commercial PCR assays to detect toxigenic Clostridioides difficile in the feces of puppies
por: Anis, Eman, et al.
Publicado: (2021)

Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
por: Elsaid, Mohamed I., et al.
Publicado: (2020)

Clostridioides difficile toxin is infrequently detected in inflammatory bowel disease and does not associate with clinical outcomes
por: Bernard, Rachel, et al.
Publicado: (2022)

Changes in IgA-targeted microbiota following fecal transplantation for recurrent Clostridioides difficile infection
por: Huus, Kelsey E, et al.
Publicado: (2020)

Diagnostic Methods of Clostridioides difficile Infection and Clostridioides difficile Ribotypes in Studied Sample
por: Novakova, Elena, et al.
Publicado: (2021)

Switching From Ceftriaxone to Cefotaxime Significantly Contributes to Reducing the Burden of Clostridioides difficile infections
por: Wendt, Sebastian, et al.
Publicado: (2020)

Environmental approaches to controlling Clostridioides difficile infection in healthcare settings
por: Carling, Philip C., et al.
Publicado: (2023)

Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with Clostridioides difficile infection with and without sepsis
por: Amin, Alpesh, et al.
Publicado: (2022)

Safety of fecal microbiota, live-jslm (REBYOTA(™)) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials
por: Lee, Christine, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cnvudv719os0h5a3kvdemftkhu